期刊
DRUG DISCOVERY TODAY
卷 24, 期 3, 页码 726-736出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.01.018
关键词
-
资金
- National Key R&D Program of China [2017YFD0502200, 2017YFD0502300]
- National Natural Science Foundation of China [31772739, 31572515]
The development of highly effective antiviral agents has been a major objective in virology and pharmaceutics. Drug repositioning has emerged as a cost-effective and time-efficient alternative approach to traditional drug discovery and development. This new shift focuses on the repurposing of clinically approved drugs and promising preclinical drug candidates for the therapeutic development of host-based antiviral agents to control diseases caused by coronavirus and influenza virus. Host-based antiviral agents target host cellular machineries essential for viral infections or innate immune responses to interfere with viral pathogenesis. This review discusses current knowledge, prospective applications and challenges in the repurposing of clinically approved and preclinically studied drugs for newly indicated antiviral therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据